Vertex Remains On Track With Telaprevir For 2010 NDA, 2011 Anticipated Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Looking to be the leader in STAT-C combo therapy for hepatitis C, Vertex also plans trial testing telaprevir with VX-222.